Pulmonary infections in patients with acute myeloid leukemia receiving frontline treatment with hypomethylating agents

References

• Short NJ, Kantarjian H. Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: past discoveries and future directions. Am J Hematol. 2022;97(12):1616–1626. doi:10.1002/ajh.26667
   PubMed Web of Science ®Google Scholar
  Giagounidis A. Current treatment algorithm for the management of lower-risk MDS. Hematology Am Soc Hematol Educ Program. 2017;2017(1):453–459. doi:10.1182/asheducation-2017.1.453
   PubMed Web of Science ®Google Scholar
• Saiz-Rodríguez M, Labrador J, Cuevas B, et al. Use of azacitidine or decitabine for the up-front setting in acute myeloid leukaemia: a systematic review and meta-analysis. Cancers. 2022;14(7):5677. doi:10.3390/cancers13225677
   PubMedGoogle Scholar
• Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98(3):502–526. doi:10.1002/ajh.26822
   PubMed Web of Science ®Google Scholar
• Maschmeyer G, Bullinger L, Garcia-Vidal C, et al. Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the european conference on infections in leukemia (ECIL), a joint venture of the european group for blood and marrow transplantation (EBMT), the european organization for research and treatment of cancer (EORTC), the international immunocompromised host society (ICHS) and the european leukemia net (ELN). Leukemia. 2022;36(5):1215–1226. doi:10.1038/s41375-022-01556-7
   PubMed Web of Science ®Google Scholar
• Stemler J, de Jonge N, Skoetz N, et al. Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the european hematology association. Lancet Haematol. 2022;9(5):e361–e373. doi:10.1016/S2352-3026(22)00073-4
   PubMed Web of Science ®Google Scholar
• Zhu LX, Chen RR, Wang LL, et al. A real-world study of infectious complications of venetoclax combined with decitabine or azacitidine in adult acute myeloid leukemia. Support Care Cancer. 2022;30(8):7031–7038. doi:10.1007/s00520-022-07126-y
   PubMed Web of Science ®Google Scholar
• Wang ST, Chou CH, Chen TT, et al. High rate of invasive fungal infections during early cycles of azacitidine for patients with acute myeloid leukemia. Front Cell Infect Microbiol. 2022;12:1012334. doi:10.3389/fcimb.2022.1012334
   PubMed Web of Science ®Google Scholar
• Schuck A, Goette MC, Neukirchen J, et al. A retrospective study evaluating the impact of infectious complications during azacitidine treatment. Ann Hematol. 2017;96(7):1097–1104. doi:10.1007/s00277-017-3001-2
   PubMed Web of Science ®Google Scholar
• Pomares H, Arnan M, Sánchez-Ortega I, et al. Invasive fungal infections in AML/MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis? Mycoses. 2016;59(8):516–519. doi:10.1111/myc.12500
   PubMed Web of Science ®Google Scholar
• Falantes JF, Calderon C, Marquez-Malaver FJ, et al. Patterns of infection in patients with myelodysplastic syndromes and acute myeloid leukemia receiving azacitidine as salvage therapy. Implications for primary antifungal prophylaxis. Clin Lymphoma Myeloma Leuk. 2014;14(1):80–86. doi:10.1016/j.clml.2013.09.014
   PubMed Web of Science ®Google Scholar
• Merkel D, Filanovsky K, Gafter-Gvili A, et al. Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study. Am J Hematol. 2013;88(2):130–134. doi:10.1002/ajh.23368
   PubMed Web of Science ®Google Scholar
• Latagliata R, Niscola P, Fianchi L, et al. Pulmonary infections in patients with myelodysplastic syndromes receiving frontline azacytidine treatment. Hematol Oncol. 2020;38(2):189–196. doi:10.1002/hon.2710
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. doi:10.1182/blood-2016-03-643544
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447. doi:10.1182/blood-2016-08-733196
   PubMed Web of Science ®Google Scholar
• De Pauw B, Walsh TJ, Donnelly JP, et al. European organization for research and treatment of cancer/invasive fungal infections cooperative group; national institute of allergy and infectious diseases mycoses study group (EORTC/MSG) consensus group. Revised definitions of invasive fungal disease from the european organization for research and treatment of cancer/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group (EORTC/MSG) Consensus group. Clin Infect Dis. 2008;46(12):1813–1821. doi:10.1086/588660
   PubMed Web of Science ®Google Scholar
• Sekeres MA, Guyatt G, Abel G, et al. American society of hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. Blood Adv. 2020;4(15):3528–3549. doi:10.1182/bloodadvances.2020001920
   PubMed Web of Science ®Google Scholar
• Zhang A, Johnson T, Abbott D, et al. Incidence of invasive fungal infections in patients with previously untreated acute myeloid leukemia receiving venetoclax and azacitidine. Open Forum Infect Dis. 2022;9(10):ofac486.
   PubMed Web of Science ®Google Scholar
• Chen EC, Liu Y, Harris CE, et al. Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax. Leuk Lymphoma. 2022;63(8):1934–1941. doi:10.1080/10428194.2022.2047964
   PubMed Web of Science ®Google Scholar